You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Exploring Emerging Food Allergy Treatments: At the Cutting Edge of Care

  • Authors: Edwin Kim, MD, MS
  • CME / ABIM MOC Released: 7/19/2023
  • Valid for credit through: 7/19/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.25 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for allergists and clinical immunologists, primary care physicians, pediatricians, nurse practitioners, physician assistants, and other clinicians who treat patients with food allergy.

The goal of this activity is for learners to be better able to describe clinical implications of emerging treatments for food allergies.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Unmet medical needs for the management of food allergies
    • Key data on emerging biologics for food allergies
  • Demonstrate greater confidence in their ability to
    • Describe clinical implications of emerging treatments for food allergies


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


  • Edwin Kim, MD, MS

    Associate Professor of Medicine
    Division Chief
    UNC Pediatric Allergy & Immunology
    UNC Allergy & Immunology Fellowship Program
    UNC Food Allergy Initiative
    Chapel Hill, North Carolina


    Edwin Kim, MD, MS, has the following relevant financial relationships:
    Consultant or advisor for: ALK-Abello; AllerGenis; Allergy Therapeutics Ltd; Belhaven Biopharma; Genentech, Inc.; Kenota Health; Nutricia; Revolo Biotherapeutics; Ukko Inc.  
    Contracted researcher for: ALK-Abello; Alladapt; DBV Technologies; Genentech, Inc.; Novartis; Ukko Inc.
    Stock options from: Belhaven Biopharma


  • Karen Badal, MD, MPH

    Senior Medical Education Director, Medscape, LLC


    Karen Badal, MD, MPH, has no relevant financial relationships.

  • Ashley Stumvoll, MRes

    Associate Medical Writer, Medscape, LLC


    Ashley Stumvoll, MRes, has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements


Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Exploring Emerging Food Allergy Treatments: At the Cutting Edge of Care

Authors: Edwin Kim, MD, MSFaculty and Disclosures

CME / ABIM MOC Released: 7/19/2023

Valid for credit through: 7/19/2024, 11:59 PM EST



  1. Gupta RS, et al. Prevalence and severity of food allergies among US adults. JAMA Netw Open. 2019;2:e185630.
  2. Warren CM, et al. Epidemiology and burden of food allergy. Curr Allergy Asthma Rep. 2020;20:6.
  3. Davis CM, et al. Health disparities in allergic and immunologic conditions in racial and ethnic underserved populations: a work group report of the AAAAI Committee on the Underserved. J Allergy Clin Immunol. 2021;147:1579-1593.
  4. Teufel M, et al. Psychological burden of food allergy. World J Gastroenterol. 2007;13:3456.
  5. Shroba J, et al. Food insecurity in the food allergic population: a work group report of the AAAAI Adverse Reactions to Foods Committee. J Allergy Clin Immunol Pract. 2022;10:81-90.
  6. Tepler E, et al. Health disparities in pediatric food allergy. Ann Allergy Asthma Immunol. 2022;129:417-423.
  7. Gupta R, et al. The economic impact of childhood food allergy in the United States. JAMA Pediatr. 2013;167:1026-1031.
  8. Reisacher WR, et al. Patient adherence to allergy immunotherapy. Curr Opin Otolaryngol Head Neck Surg. 2013;21:256-262.
  9. Iweala OI, et al. Food allergy. Curr Gastroenterol Rep. 2018;20:17.
  10. Portnoy J, et al. Eight tips for the implementation of the first licenced peanut allergy oral immunotherapy into clinical practice. Allergy Asthma Clin Immunol. 2022;18:37.
  11. Patrawala S, et al. Real-world adoption of FDA-approved peanut oral immunotherapy with palforzia. J Allergy Clin Immunol Pract. 2022;10:1120-1122.e1.
  12. Fleischer DM, et al. Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. J Allergy Clin Immunol. 2013;131:119-127.e7.
  13. Kim EH, et al. Open-label study of the efficacy, safety, and durability of peanut sublingual immunotherapy in peanut-allergic children. J Allergy Clin Immunol. 2023;151:1558-1565.e6.
  14. Kim EH, et al. Food allergy immunotherapy: oral immunotherapy and epicutaneous immunotherapy. Allergy. 2020;75:1337-1346.
  15. Jones SM, et al. Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults. J Allergy Clin Immunol. 2017;139:1242-1252.e9.
  16. Greenhawt M, et al. Phase 3 trial of epicutaneous immunotherapy in toddlers with peanut allergy. N Engl J Medicine. 2023;388:1755-1766.
  17. Jones SM, et al. State of the art on food allergen immunotherapy: oral, sublingual, and epicutaneous. J Allergy Clin Immunol. 2014;133:318-323.
  18. Calvani M, et al. Non–IgE- or mixed IgE/non–IgE-mediated gastrointestinal food allergies in the first years of life: old and new tools for diagnosis. Nutrients. 2021;13:226.
  19. Sampath V, et al. Can food allergy be cured? What are the future prospects? Allergy. 2020;75:1316-1326.
  20. Omalizumab [prescribing information]. Approved 2003. Revised July 2016.
  21. Tontoni C, et al. Novel approaches in the inhibition of IgE mast cell reactivity in food allergy. Front Immunol. 2021;12:613461.
  22. Bird JA, et al. Modified peanut oral immunotherapy protocol safely and effectively induces desensitization. J Allergy Clin Immunol Pract. 2015;3:433-435.e3
  23. Varshney P, et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol. 2011;127:654-660
  24. Savage JH, et al. Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. J Allergy Clin Immun 2012;130:1123-1129.e2.
  25. Brandström J, et al. Individually dosed omalizumab: an effective treatment for severe peanut allergy. Clin Exp Allergy. 2017;47:540-550.
  26. Fiocchi A, et al. Impact of omalizumab on food allergy in patients treated for asthma: a real-life study. J Allergy Clin Immunol Pract. 2019;7:1901-1909.e5.
  27. Wood RA, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy. J Allergy Clin Immun 2016;137:1103-1110.e11.
  28. MacGinnitie AJ, et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol. 2017;139:873-881.e8.
  29. Andorf S, et al. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial. Lancet Gastroenterol Hepatol. 2018;3:85-94.
  30. Wood RA, et al. Protocol design and synopsis: omalizumab as monotherapy and as adjunct therapy to multiallergen OIT in children and adults with food allergy (OUtMATCH). J Allergy Clin Immunol Global. 2022;1:225-232.
  31. Omalizumab as monotherapy and as adjunct therapy to multi-allergen oral immunotherapy (OIT) in food allergic children and adults (CoFAR-11). Accessed July 10, 2023.
  32. Wood RA, et al. The rationale for development of ligelizumab in food allergy. World Allergy Organ J. 2022;15:100690.
  33. Gasser P, et al. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun. 2020;11:165.
  34. A 52-week, multi-center, randomized, double-blind placebo-controlled study to assess the clinical efficacy and safety of ligelizumab (qge031) in decreasing the sensitivity to peanuts in patients with peanut allergy. Accessed July 10, 2023.
  35. Sindher SB, et al. Treatment of food allergy: oral immunotherapy, biologics, and beyond. Ann Allergy Asthma Immunol. 2023:S1081-1206(23)00309-5. doi: 10.1016/j.anai.2023.04.023. [Epub ahead of print]
  36. Albuhairi S, et al. Biologics and novel therapies for food allergy. Immunol Allergy Clin North Am. 2021;41:271-283.
  37. Patil SU, et al. Emerging food allergy biomarkers. J Allergy Clin Immunol Pract. 2020;8:2516-2524.
  38. Santos AF, et al. Basophil activation test: mechanisms and considerations for use in clinical trials and clinical practice. Allergy. 2021;76:2420-2432.
  39. Baba AE, et al. Geographical discrepancy in oral food challenge utilization based on Canadian billing data. Allergy Asthma Clin Immunol. 2023;19:5.
  40. Foong R, et al. Biomarkers of diagnosis and resolution of food allergy. Pediatr Allergy Immu. 2021;32:223-233.
  41. Czolk R, et al. IgE-mediated peanut allergy: current and novel predictive biomarkers for clinical phenotypes using multi-omics approaches. Front Immunol. 2021;11:594350.
  42. McGowan EC, et al. Food allergy, eosinophilic esophagitis, and the enigma of IgG4. Ann Allergy Asthma Immunol. 2019;122:563-564.


« Return to: Exploring Emerging Food Allergy Treatments: At the Cutting Edge of Care
  • Print